Sementis is an Australian unlisted public biotechnology company based in Adelaide, South Australia that is dedicated to the research and development of new vaccines to tackle the world’s most challenging diseases.

The Company’s mission is to deliver an adaptable vaccine platform in response to rapidly emerging diseases of pandemic proportion and also to treat diseases of high unmet medical need including allergies.

Where it started

Sementis was founded in 2009, based on the invention of the SCV platform system. This technology combines a viral vector genetically engineered for safety with a commercial industry-standard suspension cell line to overcome the manufacturing issues associated with primary cells or designer cell lines.

Discover SCV

Research Pipeline

Corporate Governance